FDA Commissioner Marty Makary said the agency is seeking to speed new US clinical trial processes by reducing the amount of data needed to start a trial, focusing on the portions tied to safety. The push comes as FDA leadership signals a more streamlined approach to trial authorization amid increasing global competition for drug development timelines.